Methods for the cytological analysis of cervical cells
DC
First Claim
Patent Images
1. A method for detecting chromosomal abnormalities in a plurality of cervical cells, said method consisting of:
- hybridizing a first nucleic acid probe to a target nucleic acid sequence on chromosome 3q of the cervical cells to form a first hybridization complex;
hybridizing a second nucleic acid probe to a target nucleic acid on chromosome 5p of the cervical cells to form a second hybridization complex;
hybridizing a nucleic acid control probe to centromere of chromosome 7 (CEN7) to form a third hybridization complex;
detecting a first signal indicative of the formation of the first hybridization complex on chromosome 3q;
detecting a second signal indicative of the formation of the second hybridization complex on chromosome 5p;
detecting a third signal indicative of the formation of the third hybridization complex on CEN7,wherein said first, second and third signals indicative of formation of first, second and third hybridization complexes is indicative of an increase in chromosomal copy number in the cervical cells, and wherein the increase in chromosomal copy number is indicative of the chromosomal abnormalities in the cervical cells.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.
11 Citations
100 Claims
-
1. A method for detecting chromosomal abnormalities in a plurality of cervical cells, said method consisting of:
-
hybridizing a first nucleic acid probe to a target nucleic acid sequence on chromosome 3q of the cervical cells to form a first hybridization complex; hybridizing a second nucleic acid probe to a target nucleic acid on chromosome 5p of the cervical cells to form a second hybridization complex; hybridizing a nucleic acid control probe to centromere of chromosome 7 (CEN7) to form a third hybridization complex; detecting a first signal indicative of the formation of the first hybridization complex on chromosome 3q; detecting a second signal indicative of the formation of the second hybridization complex on chromosome 5p; detecting a third signal indicative of the formation of the third hybridization complex on CEN7, wherein said first, second and third signals indicative of formation of first, second and third hybridization complexes is indicative of an increase in chromosomal copy number in the cervical cells, and wherein the increase in chromosomal copy number is indicative of the chromosomal abnormalities in the cervical cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
-
-
51. A method for detecting chromosomal abnormalities in a plurality of cervical cells, said method comprising:
-
hybridizing a first nucleic acid probe to a target nucleic acid sequence on chromosome 3q of the cervical cells to form a first hybridization complex; hybridizing a second nucleic acid probe to a target nucleic acid on chromosome 5p of the cervical cells to form a second hybridization complex; hybridizing a nucleic acid control probe to centromere of chromosome 7 (CEN7) to form a third hybridization complex; detecting a first signal indicative of the formation of the first hybridization complex on chromosome 3q; detecting a second signal indicative of the formation of the second hybridization complex on chromosome 5p; detecting a third signal indicative of the formation of the third hybridization complex on CEN7, wherein said first, second and third signals indicative of formation of first, second and third hybridization complexes is indicative of an increase in chromosomal copy number in the cervical cells, and wherein a lack of chromosomal abnormalities in the cervical cells is shown by normal ploidy and (1) less than 1.0% of analyzed cells with an increase in both 3q copy number and 5p copy number; (2) gains of only 3q copy number in less than 0.9% of the analyzed cells;
or(3) gains of only 5p copy number in less than 0.7% of the analyzed cells. - View Dependent Claims (52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeNeoDiagnostix, Inc. (Bristol-Myers Squibb Company)
-
Original AssigneeNeoDiagnostix, Inc. (Bristol-Myers Squibb Company)
-
InventorsEndress, Gregory Anton, Upender, Madhvi, Light, Elizabeth, Cain, Colyn
-
Primary Examiner(s)Gussow, Anne
-
Assistant Examiner(s)Brown, Mindy G
-
Application NumberUS12/506,985Publication NumberTime in Patent Office1,603 DaysField of SearchNoneUS Class Current435/6.11CPC Class CodesA61P 35/00 Antineoplastic agentsC12N 15/1068 Template (nucleic acid) med...C12Q 1/6816 characterised by the detect...C12Q 1/6841 In situ hybridisationC12Q 1/6883 for diseases caused by alte...C12Q 1/6886 for cancer immunoassay for ...C12Q 2600/112 Disease subtyping, staging ...C12Q 2600/118 Prognosis of disease develo...C12Q 2600/156 Polymorphic or mutational m...
